Mechanism of Action: Tyrosine Kinase 2 Inhibitors

Drugs with Mechanism of Action: Tyrosine Kinase 2 Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes			Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes			Y	Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes			Y	Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes

Market Dynamics and Patent Landscape for Tyrosine Kinase 2 (TYK2) Inhibitors

Last updated: March 21, 2026

What is the current market size for TYK2 inhibitors?

The global TYK2 inhibitor market was valued at approximately $600 million in 2022. It is projected to reach $1.8 billion by 2030, with a compound annual growth rate (CAGR) of 13.4% from 2023 to 2030. Growth drivers include increasing prevalence of autoimmune diseases like psoriasis and rheumatoid arthritis (RA), along with escalating adoption of targeted therapies.

Which key drugs are leading in the TYK2 inhibitor landscape?

Approved drugs:

• Deucravacitinib (AbbVie): First in class approved by the FDA in September 2022 for moderate-to-severe plaque psoriasis. It has shown efficacy in clinical trials for RA and other autoimmune conditions.
• BMS-986202 (Bristol-Myers Squibb): Phase 2 pipeline candidate targeting multiple autoimmune indications.

Pipeline drugs:

• PF-06826647 (Pfizer): Phase 3 development for psoriasis and RA.
• LY3007113 (Lilly): Phase 2 candidate for inflammatory diseases.
• Multiple candidates in early-stage clinical testing aim to expand indications.

How do patent expirations affect market prospects?

Deucravacitinib

• Patent expiration is projected around 2032. Patents covering the core compound and formulations will influence generic entry.
• AbbVie’s patent portfolio includes composition-of-matter patents extending protection up to 2032, with supplementary method-of-use patents until 2035.

Competitor patent landscape

• Multiple companies hold patents related to novel TYK2 inhibitors, though many are layered with secondary patents covering specific formulations and methods.
• Patent thickets challenge generic development; infringement risk is minimized until key patents expire.

Impact on market competition

• Expiry of primary patents around 2032 will open opportunities for biosimilars and generics, potentially reducing prices and increasing access.
• Patent barriers currently favor innovation with limited competition.

What are the primary therapeutic indications and unmet needs?

Indications:

• Psoriasis (approved)
• Rheumatoid arthritis (clinical trials)
• Inflammatory bowel disease (phase 2/3 trials)
• Alopecia areata (investigational)

Unmet needs:

• Long-term safety data
• Efficacy in refractory cases
• Broader indication coverage

How does pricing and reimbursement influence market growth?

• List prices for deucravacitinib are approximately $60,000 per year in the U.S., similar to biologics.
• Reimbursement landscape favors new targeted therapies; insurance coverage expands as clinical benefits are demonstrated.
• Cost-effectiveness evaluations are ongoing to support formulary inclusion.

What are the competitive threats and barriers to market expansion?

• Safety concerns, including infection risks and off-target effects, can hinder uptake.
• Emergence of alternative pathways (e.g., JAK inhibitors) presents competition.
• Patent litigation may delay market entry for biosimilars and generics post-patent expiry.

Future outlook and growth opportunities

• Expansion into additional autoimmune diseases, including vitiligo and lupus.
• Combination therapy models with existing biologics.
• Investment in predictive biomarkers for tailored therapy.

Summary of patent landscape details

Patent Type	Assignee	Expiry Year	Scope
Composition-of-matter patents	AbbVie	2032	Core molecular structure
Formulation patents	Multiple	2032–2035	Delivery methods and formulations
Method-of-use patents	AbbVie & others	2035	Specific indications
Secondary patents	Various	2033–2040	Manufacturing processes, biomarkers

Key Takeaways

• The TYK2 inhibitor market is growing rapidly, driven by the approval of deucravacitinib and pipeline activity.
• Patent protection for core compounds extends until at least 2032, delaying generic competition.
• Long-term safety, broader indication approval, and pricing strategies will shape future market dynamics.
• Competition from JAK inhibitors and potential biosimilar entrants post-patent expiry are notable threats.
• Investment opportunities exist in pipeline expansion and expanding indications.

FAQs

1. When are TYK2 inhibitors expected to face generic competition?
   Patent protections for primary compounds extend until approximately 2032, with secondary patents delaying generic entry further.

2. What diseases aside from psoriasis are TYK2 inhibitors targeting?
   Rheumatoid arthritis, inflammatory bowel disease, alopecia areata, and lupus are under investigation.

3. How do TYK2 inhibitors compare to JAK inhibitors?
   TYK2 inhibitors are more selective, potentially offering fewer side effects. However, safety profiles and long-term data are still being evaluated.

4. What patent challenges exist for TYK2 inhibitors?
   Patent thickets and secondary patents create barriers for generics. Litigation over infringement is ongoing, potentially delaying market entry.

5. Are there regional variations in patent protections?
   Yes. Patent laws and extension periods differ across jurisdictions, impacting global market entry strategies.

References

1. MarketsandMarkets. (2022). TYK2 inhibitors market analysis.
2. U.S. Food and Drug Administration. (2022). Approval of deucravacitinib.
3. PatentScope. (2023). Patent filings for TYK2 inhibitors.
4. IQVIA. (2022). Biopharma forecast report.
5. European Patent Office. (2023). Patent data on TYK2 inhibitors.